MARKET WIREYahoo Finance • 1d ago
COLL vs. DSNKY: Which Stock Is the Better Value Option?Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
Why COLL Stock slipped -0.50% Today — RQD Quant Desk Flash
$23.68 -0.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.61
Collegium Pharmaceutical Inc. (COLL) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $774.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on COLL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $23.68 (-0.50% 1D, market cap $774.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, COLL ranks #169 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COLL compare to HELP and ANNX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable C- (59/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $774.1M) and ANNX (Annexon Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $767.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COLL?
▼
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.61 (-0.28%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 42% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw C · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COLL)Realized 20D OHLCV Swing Band: ±6.8%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY COLL SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 42% FCF Margin ($327.6M FCF) & 59.3% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)
Macro rate sensitivity & RSI-14 (56.1) create a -12 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$21.53+7.9% Next Q
51
Q2 (-2Q)Grade C-$23.23-1% Next Q
54
Q3 (-1Q)Grade C$23.00+3% Next Q
56
CurrentGrade C-$23.68+0.2% Hist 90D α
59
Trajectory: C- (51) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the COLL Bull Thesis Could Fail
Even with a 59/100 (C-) score, COLL faces multiple-compression risk if 12.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.17) or 200D SMA ($33.01) invalidates the momentum regime and cuts Target Base ($23.79) toward Bear Floor ($18.56).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $COLL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “COLL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why COLL Stock slipped -0.50% Today — RQD Quant Desk Flash
Collegium Pharmaceutical Inc. (COLL) slipped -0.50% to $23.68, trading at 8% of its 52-week range ($21.43 – $50.79). Solid 59.3% gross margin (85% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 8% of its 52-week range ($21.43 – $50.79) with RSI-14 at 56.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.8% around $23.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 59.3% gross margin and $327.6M annual free cash flow.
Live COLL Headlines & Catalysts
RISK WATCHSeeking Alpha • 1d ago
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)Seeking Alpha report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocksYahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
An investor reports 5% or less of Collegium Pharmaceutical (COLL) and shares voting power.Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHDYahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
A planned 2027 soccer program will train coaches to better support kids with ADHDStock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 2d ago
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Operating Leverage and Financial Strength Anchor Champion Homes (SKY) Investment ThesisThird Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
CATALYSTYahoo • 4d ago
Versigent (VGNT) is Unlocking Value Through Independent Growth and Capital AllocationThird Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (COLL Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
COLL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.52%⚡ TESTING RESISTANCE
2026-11-03O $24.03H $24.03L $23.68C $23.68VOL 402.0K
RES: $24.16SUP: $15.89SMA50: $23.17SMA200: $33.01
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
COLL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
3.2%/yr Implied 5Y Growth
vs. +23.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on COLL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for COLL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COLL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COLL)
Health Care Rank #169 of 1015
⚔️ HELP vs COLL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (COLL vs. HELP, ANNX, ARDX, AVBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Collegium Pharmaceutical Inc. (COLL) ranks #169 by composite RQD confidence (59/100, grade C-) and #384 by equity capitalization ($774.8M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COLL
ACTIVE
Collegium Pharmaceutical Inc. | C- | 59/100 | 12.4x | 59.3% | 85.0% | -0.50% | $774.8M | Benchmark Subject |
| HELP Helus Pharma Inc. | D+ | 53/100 | — | — | — | -16.94% | $774.1M | /help-vs-coll → |
| ANNX Annexon Inc. | E | 30/100 | — | — | -35.0% | -2.72% | $767.8M | /annx-vs-coll → |
| ARDX Ardelyx Inc. | E | 24/100 | — | 90.3% | -32.7% | 0.00% | $755.0M | /ardx-vs-coll → |
| AVBP ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -10.22% | $733.2M | /avbp-vs-coll → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001267565 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Collegium Pharmaceutical Inc. (COLL) reported GAAP revenue of $780.6M (+23.6% vs. FY2024 revenue of $631.4M , and +37.7% cumulative change since FY2023) , GAAP net income of $63.0M, operating cash flow of $329.3M, and free cash flow of $327.6M (+61.1% YoY). On the balance sheet, COLL closed FY2025 with $1.66B in total assets against $0 in total debt (Altman Z-Score: 1.27, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $780.6M | $63.0M | $329.3M | $327.6M | $1.66B | — |
| FY2024 (FY) | 2024-12-31 | $631.4M | $69.0M | $205.0M | $203.3M | $1.66B | — |
| FY2023 (FY) | 2023-12-31 | $566.8M | $48.0M | $274.7M | $274.7M | — | — |
3. COLL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $23.68 (-0.50% 1D, market cap $774.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, COLL ranks #169 in composite RQD confidence.
How does COLL compare to HELP and ANNX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable C- (59/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $774.1M) and ANNX (Annexon Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $767.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COLL?
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COLL trading relative to its 50-day, 200-day, and 52-week technical levels?
COLL last traded at $23.68 (-0.50% on volume of 600,695 shares), positioning the stock +2.20% above its 50-day simple moving average ($23.17) and -28.26% below its 200-day simple moving average ($33.01). Across its 52-week range of $21.43 to $50.79, COLL sits at the 7.7% percentile with a 14-day RSI of 56.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($22.07 to $25.29).
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ SEC XBRL & RQD VERIFIED
COLL — Collegium Pharmaceutical Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Collegium Pharmaceutical Inc. (COLL) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $23.68 (-0.50% 1D, market capitalization $774.8M).
- Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of 59.3%, operating margin of 23.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (8/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.27, Piotroski F-Score of 7/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Collegium Pharmaceutical Inc. (COLL) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.8B. Per the recent news wire, the company is described as repositioning its focus from pain management toward ADHD.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Collegium Pharmaceutical Inc. (COLL) reported $780.6M in annual revenue (up from $631.4M in FY2024, +23.6% YoY) and $63.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($566.8M revenue, $48.0M net income) through FY2025, COLL scaled operating cash flow to $329.3M and free cash flow to $327.6M, backed by $1.66B in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C- • RQD 59/100): Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $21.43 – $50.79 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 12.4x trailing P/E and 3.0x EV/EBITDA against 23.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), COLL carries a macro regime beta of 1.00 and gross margin of 59.3%.
- Key Question #1: Can COLL sustain or expand its 23.0% operating margin and 85.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $780.6M and free cash flow of $327.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is COLL's 10.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
COLL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Collegium Pharmaceutical Inc. (COLL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
COLL vs. DSNKY: Which Stock Is the Better Value Option? Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 1d ago
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL) Seeking Alpha report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript Benzinga report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
An investor reports 5% or less of Collegium Pharmaceutical (COLL) and shares voting power. Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
A planned 2027 soccer program will train coaches to better support kids with ADHD Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 2d ago
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
COLL Bull vs. Bear Conversation Board — What's Your Call at $23.68?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COLL 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $31.42 (+32.0%)
📌 Pinned Debate ROIC of 85% combined with a forward P/E of 10.4 and reported FY 2025 free cash flow of $327.6M suggests strong capital efficiency at a
Long COLL at $23.80 targeting $31.42. ROIC of 85% combined with a forward P/E of 10.4 and reported FY 2025 free cash flow of $327.6M suggests strong capital efficiency at a low earnings multiple.. Institutional whale score is 8/20 and the risk/reward vs. the $21.43 52-week low is skewed heavily in favor of bulls.
EarningsSniper 🐂 BULL
Both sides have a point here — COLL's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $18.56 (-22.0%)
Spot @ $23.80 A RED RISK WATCH item on a narrow guidance cut, a 0% FCF yield, an Altman Z of 1.27, and FY 2025 net income falling to $63.0M from $69.
I respect the product at Collegium Pharmaceutical Inc., but the stock at $23.80 is a different story. A RED RISK WATCH item on a narrow guidance cut, a 0% FCF yield, an Altman Z of 1.27, and FY 2025 net income falling to $63.0M from $69.0M despite higher revenue.. FCF yield is 0.0% and RQD sits at 59/100 (C-) — why pay up here when you can wait for next quarter's numbers?